You are here


The real lesson from Eli Lilly's Alzheimer's drug trial failure

Digging through unsuccessful drug experiments to find justification for moving forward with medicines is a recipe for failing again.

New York

THE most anticipated pharma news of 2016 lived down to expectations.   Following in the footsteps of nearly every other company that has sought to treat Alzheimer's disease, Eli Lilly announced last Wednesday that its Alzheimer's drug solanuzemab (sola) failed a huge Phase 3

Market voices on:


Receive $80 Grab vouchers valid for use on all Grab services except GrabHitch and GrabShuttle when you subscribe to BT All-Digital at only $0.99*/month.

Find out more at

Powered by GET.comGetCom